CytomX Rips Higher After Mask-Activation Thesis Gains Traction: Upgrade to Long
CTMX popped to a 52-week high on massive volume as investors price in clearer evidence that CytomX's Probody platform is delivering conditionally activated activity in tumors. Fundamentals remain mixed, but the technical breakout, rising short-covering, and upcoming clinical readouts make a disciplined long trade attractive for a mid-term swing.